13:11 , Feb 16, 2018 |  BC Week In Review  |  Clinical News

Boehringer discontinues PDE-9A inhibitor for AD

Boehringer Ingelheim GmbH (Ingelheim, Germany) discontinued development of BI 409306 to treat Alzheimer's disease after the candidate missed the efficacy endpoints in two Phase II trials in the indication. BI 409306 is a phosphodiesterase-9A (PDE-9A)...
21:53 , Feb 9, 2018 |  BC Extra  |  Clinical News

Boehringer discontinues PDE-9A inhibitor for AD

Boehringer Ingelheim GmbH (Ingelheim, Germany) discontinued development of BI 409306 to treat Alzheimer's disease after the candidate missed the efficacy endpoints in two Phase II trials in the indication. BI 409306 is a phosphodiesterase-9A (PDE-9A)...
07:00 , Aug 4, 2016 |  BC Innovations  |  Finance

2Q16 Public-Private Partnership Roundup

A new consortia revival helped boost public-private partnerships (PPPs) in 2Q16 to the highest total in two years. Newly announced preclinically focused deals jumped 30% over the relatively sluggish first quarter, from 56 PPPs to...